Roivant Sciences Ltd. reported an insider ownership change involving James C. Momtazee, a non-employee director, tied to an equity grant dated July 17, 2026. The Form 4 was filed on July 21, 2026, and covers Common Shares of Roivant Sciences, ticker ROIV. The reported transaction reflects an award of Roivant Common Shares made under the company’s Non-Employee Director Compensation Plan. According to the explanatory note, the award was fully vested as of the grant date, meaning Momtazee received the shares without any remaining vesting conditions attached to this particular grant. The filing excerpt does not provide the number of shares awarded, the transaction price, a transaction code, or Momtazee’s beneficial ownership after the transaction. Because the shares were granted as director compensation rather than purchased in the open market, the economic significance is primarily that Roivant compensated a board member with fully vested equity, aligning director compensation with shareholder value. The filing also notes an Exhibit 24 Power of Attorney, indicating that the report may have been signed or submitted by an authorized representative on Momtazee’s behalf.